Ascendis Pharma A/SASNDNASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P100
Near historical high
vs 2Y Ago
46.9x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 3108.25% |
| Q3 2025 | 117.98% |
| Q2 2025 | 22.22% |
| Q1 2025 | 82.85% |
| Q4 2024 | -54.70% |
| Q3 2024 | 8.19% |
| Q2 2024 | 39.43% |
| Q1 2024 | -140.01% |
| Q4 2023 | 66.26% |
| Q3 2023 | 18.15% |
| Q2 2023 | -3.67% |
| Q1 2023 | -1.83% |
| Q4 2022 | -42.62% |
| Q3 2022 | 20.39% |
| Q2 2022 | 4.82% |
| Q1 2022 | -5.07% |
| Q4 2021 | -17.72% |
| Q3 2021 | 8.39% |
| Q2 2021 | -37.84% |
| Q1 2021 | 9.82% |
| Q4 2020 | -51.40% |
| Q3 2020 | -2.61% |
| Q2 2020 | 15.66% |
| Q1 2020 | -44.80% |
| Q4 2019 | 17.70% |
| Q3 2019 | -886.22% |
| Q2 2019 | 90.20% |
| Q1 2019 | -72.92% |
| Q4 2018 | 22.96% |
| Q3 2018 | -132.51% |
| Q2 2018 | 44.50% |
| Q1 2018 | -51.04% |
| Q4 2017 | 5.81% |
| Q3 2017 | -7.34% |
| Q2 2017 | -11.55% |
| Q1 2017 | -29.02% |
| Q4 2016 | -4.69% |
| Q3 2016 | -22.63% |
| Q2 2016 | 13.09% |
| Q1 2016 | -45.15% |